|MDACC Study No:||CERN08-02 (clinicaltrials.gov NCT No: NCT00826241)|
|Title:||A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma|
|Principal Investigator:||Mark R. Gilbert|
|Treatment Agent:||Lapatinib; Temozolomide|
|Study Description:||The goal of this clinical research study is to learn if lapatinib when given in |
combination with temozolomide can help to control ependymoma that has come back
after treatment. The safety of this combination will also be studied.